We are excited to announce the launch of our equity crowdfunding campaign on StartEngine. This campaign offers individuals the unique opportunity to invest in and own a part of a company dedicated to revolutionizing cancer diagnosis tools.
Epi One’s groundbreaking diagnostic platform aims to detect cancer early, accurately, and affordably. Utilizing a simple blood test, Epi One’s technology identifies DNA-based biomarkers, providing highly accurate results in as little as six hours. This innovative approach has the potential to save millions of lives by enabling early treatment and significantly improving survival rates.
Michael Marquardt, CEO of Epi One, expressed his enthusiasm for the campaign, stating: “We are incredibly excited to open up this opportunity for everyone to become a part of Epi One’s journey. Our mission is to make a significant impact in the health technology space, and with the support of our new investors, we are confident in our ability to achieve this goal. This equity crowdfunding campaign on StartEngine allows anyone to join us in shaping the future of early cancer detection.”
The equity crowdfunding campaign is now live on StartEngine, offering investors the chance to be a part of Epi One’s growth and innovation. You can find details of the offering at StartEngine’s Epi One offering page.
